Andrew J. Murphy, EVP Research at REGENERON PHARMACEUTICALS, INC. (REGN), sold 25,174 shares at $642.76 ($15.2M) on 2021-11-16, disclosed to the SEC on 2021-11-17.
Open-market sale of $15.2M REGN by EVP Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 1,645 | $0 | 0.0% |
| 2 | $641.50 | 9,412 | $6.0M | 39.8% |
| 3 | $642.76 | 465 | $299K | 2.0% |
| 4 | $642.76 | 465 | $299K | 2.0% |
| 5 | $643.42 | 924 | $595K | 3.9% |
| 6 | $643.42 | 924 |
| $595K |
| 3.9% |
| 7 | $644.71 | 1,106 | $713K | 4.7% |
| 8 | $644.71 | 1,106 | $713K | 4.7% |
| 9 | $645.41 | 1,640 | $1.1M | 7.0% |
| 10 | $645.41 | 1,640 | $1.1M | 7.0% |
| 11 | $646.52 | 557 | $360K | 2.4% |
| 12 | $646.52 | 557 | $360K | 2.4% |
| 13 | $647.39 | 844 | $546K | 3.6% |
| 14 | $647.39 | 844 | $546K | 3.6% |
| 15 | $648.20 | 86 | $56K | 0.4% |
| 16 | $648.20 | 86 | $56K | 0.4% |
| 17 | $649.26 | 5 | $3K | 0.0% |
| 18 | $651.42 | 296 | $193K | 1.3% |
| 19 | $651.42 | 296 | $193K | 1.3% |
| 20 | $652.24 | 133 | $87K | 0.6% |
| 21 | $652.24 | 133 | $87K | 0.6% |
| 22 | $653.31 | 454 | $297K | 2.0% |
| 23 | $653.31 | 454 | $297K | 2.0% |
| 24 | $654.34 | 198 | $130K | 0.9% |
| 25 | $654.34 | 198 | $130K | 0.9% |
| 26 | $655.30 | 92 | $60K | 0.4% |
| 27 | $655.30 | 92 | $60K | 0.4% |
| 28 | $657.46 | 74 | $49K | 0.3% |
| 29 | $658.56 | 71 | $47K | 0.3% |
| 30 | $659.15 | 155 | $102K | 0.7% |
| 31 | $659.15 | 155 | $102K | 0.7% |
| 32 | $660.32 | 67 | $44K | 0.3% |
| Total | $602.66 avg | 25,174 | $15.2M | 100% |
| Filing → |
| REGN | SELL | 2024-03-15 | $11.0M | — | Filing → |
| REGN | SELL | 2023-12-06 | $10.6M | — | Filing → |
| REGN | SELL | 2023-11-15 | $10.3M | — | Filing → |